ADMA Biologics (ADMA) initiated a $125M accelerated share repurchase on 2026-03-02. This follows a recent CFO transition and prior Q3 2025 update.
ADMA BIOLOGICS announces CFO Brad Tade's retirement and appoints Terry Kohler as CFO and Treasurer. Key facts and investor implications, Feb 25, 2026.
ADMA Biologics Q3 2025: revenue up 12% and an FDA lot release boosts outlook. Key investor takeaways and context.